Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan NV    MYL   NL0011031208

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/15/2018 05/16/2018 05/17/2018 05/18/2018 05/21/2018 Date
38.5(c) 39.18(c) 40.08(c) 39.66(c) 39.55 Last
3 328 766 3 943 947 6 222 237 4 590 536 2 063 798 Volume
+0.63% +1.77% +2.30% -1.05% -0.28% Change
More quotes
Financials (USD)
Sales 2018 12 319 M
EBIT 2018 3 794 M
Net income 2018 1 351 M
Debt 2018 13 179 M
Yield 2018 -
Sales 2019 12 943 M
EBIT 2019 3 950 M
Net income 2019 1 630 M
Debt 2019 10 654 M
Yield 2019 -
P/E ratio 2018 13,01
P/E ratio 2019 10,73
EV / Sales2018 2,75x
EV / Sales2019 2,42x
Capitalization 20 658 M
More Financials
Company
Mylan N.V., is a pharmaceutical company which engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products.The company was founded on July 7, 2014 and is headquartered in Hatfield, United Kingdom. 
Sector
Pharmaceuticals
Calendar
06/29Shareholder meeting
More about the company
Surperformance© ratings of Mylan NV
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN NV
05/18GSK bets on lift from new lung drugs ahead of Advair's last gasp
RE
05/16Evolus investors frown as FDA declines to approve Botox rival
RE
05/14MYLAN : and West Virginia University Join Forces to Inspire West Virginia Youth ..
PR
05/10In Europe, Mylan's rivals try to plug EpiPen shortages
RE
05/09MYLAN : May Be Gem in Rough Generic Sector
DJ
05/09MYLAN : Statement on Supply of EpiPen® (epinephrine injection, USP) Auto-Injecto..
PU
05/09MYLAN : Reports First Quarter 2018 Results and Reaffirms 2018 Guidance
PR
05/02MYLAN : to Release First Quarter 2018 Financial Results on May 9, 2018
PR
04/25Currency and pricing squeeze GSK as new shingles vaccine shines
RE
04/25MYLAN : Adds to Growing Women's Healthcare Portfolio with Launch of Generic for ..
PR
More news
Sector news : Pharmaceuticals - NEC
05/21MERCK AND : Ebola Vaccination Begins in Democratic Republic of Congo -- Update
DJ
05/21MERCK AND : Factbox - From sterling crises to Brexit, the tests of Bank of Engla..
RE
05/21ASTRAZENECA : potassium drug finally approved, threatening Vifor
RE
05/21EU Approves GlaxoSmithKline JV's Juluca HIV Treatment
DJ
05/21MERCK AND : Ebola Vaccine Arrives in Democratic Republic of Congo
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
05/21Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching $MNK $MYL..
2
05/21Recent Research Analysts’ Ratings Updates for Mylan $MYL  
05/19Week in review: How Trump's policies moved stocks $AAPL $ZTCOY $ACIA $OCLR $T..
4
05/18$GLD $MYL $SHPG $VRX $AGN $TWX $TMUS $DISH $NXPI $AABA $AU $HZNP $TSU $NG $DI.. 
05/17Breaking down size OTM Call #Stupid paper in $MYL live now on #OptionBlock  
More tweets
Qtime:133
News from SeekingAlpha
05/18Tracking John Paulson's Paulson & Co. Portfolio - Q1 2018 Update 
05/18Investors bullish on biotechs after Trump drug pricing speech 
05/17Teva's Generic Restasis Could Punish Allergan 
05/16Generic Revlimid Could Sink Celgene 
05/15Greenlight added IAC/InterActiveCorp, exited Chemours in Q1 
Chart MYLAN NV
Duration : Period :
Mylan NV Technical Analysis Chart | MYL | NL0011031208 | 4-Traders
Technical analysis trends MYLAN NV
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 49,7 $
Spread / Average Target 25%
EPS Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Director
Rajiv Malik President & Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN NV-6.26%20 658
JOHNSON & JOHNSON-11.08%332 184
PFIZER-1.41%212 424
NOVARTIS-6.55%202 969
ROCHE HOLDING LTD.-8.90%193 622
MERCK AND COMPANY5.10%158 916